322 related articles for article (PubMed ID: 11328352)
21. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor.
Choi-Lundberg DL; Lin Q; Schallert T; Crippens D; Davidson BL; Chang YN; Chiang YL; Qian J; Bardwaj L; Bohn MC
Exp Neurol; 1998 Dec; 154(2):261-75. PubMed ID: 9878166
[TBL] [Abstract][Full Text] [Related]
22. GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine.
Tseng JL; Baetge EE; Zurn AD; Aebischer P
J Neurosci; 1997 Jan; 17(1):325-33. PubMed ID: 8987758
[TBL] [Abstract][Full Text] [Related]
23. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector.
Georgievska B; Kirik D; Rosenblad C; Lundberg C; Björklund A
Neuroreport; 2002 Jan; 13(1):75-82. PubMed ID: 11924898
[TBL] [Abstract][Full Text] [Related]
24. Intracerebroventricular glial cell line-derived neurotrophic factor improves motor function and supports nigrostriatal dopamine neurons in bilaterally 6-hydroxydopamine lesioned rats.
Bowenkamp KE; Lapchak PA; Hoffer BJ; Miller PJ; Bickford PC
Exp Neurol; 1997 May; 145(1):104-17. PubMed ID: 9184114
[TBL] [Abstract][Full Text] [Related]
25. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease.
Eslamboli A; Georgievska B; Ridley RM; Baker HF; Muzyczka N; Burger C; Mandel RJ; Annett L; Kirik D
J Neurosci; 2005 Jan; 25(4):769-77. PubMed ID: 15673656
[TBL] [Abstract][Full Text] [Related]
26. Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo.
Sullivan AM; Opacka-Juffry J; Blunt SB
Eur J Neurosci; 1998 Jan; 10(1):57-63. PubMed ID: 9753113
[TBL] [Abstract][Full Text] [Related]
27. Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease.
Cunningham LA; Su C
Exp Neurol; 2002 Apr; 174(2):230-42. PubMed ID: 11922664
[TBL] [Abstract][Full Text] [Related]
28. GDNF protects against 6-OHDA nigrostriatal lesion: in vivo study with microdialysis and PET.
Opacka-Juffry J; Ashworth S; Hume SP; Martin D; Brooks DJ; Blunt SB
Neuroreport; 1995 Dec; 7(1):348-52. PubMed ID: 8742486
[TBL] [Abstract][Full Text] [Related]
29. Progressive and extensive dopaminergic degeneration induced by convection-enhanced delivery of 6-hydroxydopamine into the rat striatum: a novel rodent model of Parkinson disease.
Oiwa Y; Sanchez-Pernaute R; Harvey-White J; Bankiewicz KS
J Neurosurg; 2003 Jan; 98(1):136-44. PubMed ID: 12546362
[TBL] [Abstract][Full Text] [Related]
30. Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease.
Ericson C; Georgievska B; Lundberg C
Eur J Neurosci; 2005 Dec; 22(11):2755-64. PubMed ID: 16324109
[TBL] [Abstract][Full Text] [Related]
31. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo.
Kearns CM; Gash DM
Brain Res; 1995 Feb; 672(1-2):104-11. PubMed ID: 7749731
[TBL] [Abstract][Full Text] [Related]
32. Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.
Yue X; Hariri DJ; Caballero B; Zhang S; Bartlett MJ; Kaut O; Mount DW; Wüllner U; Sherman SJ; Falk T
Neuroscience; 2014 Jan; 258():385-400. PubMed ID: 24291725
[TBL] [Abstract][Full Text] [Related]
33. Neuroprotective effects of GDNF against 6-OHDA in young and aged rats.
Fox CM; Gash DM; Smoot MK; Cass WA
Brain Res; 2001 Mar; 896(1-2):56-63. PubMed ID: 11277973
[TBL] [Abstract][Full Text] [Related]
34. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat.
Kirik D; Rosenblad C; Björklund A
Exp Neurol; 1998 Aug; 152(2):259-77. PubMed ID: 9710526
[TBL] [Abstract][Full Text] [Related]
35. Reversible neurochemical changes mediated by delayed intrastriatal glial cell line-derived neurotrophic factor gene delivery in a partial Parkinson's disease rat model.
Yang X; Mertens B; Lehtonen E; Vercammen L; Bockstael O; Chtarto A; Levivier M; Brotchi J; Michotte Y; Baekelandt V; Sarre S; Tenenbaum L
J Gene Med; 2009 Oct; 11(10):899-912. PubMed ID: 19639608
[TBL] [Abstract][Full Text] [Related]
36. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease.
Wang L; Muramatsu S; Lu Y; Ikeguchi K; Fujimoto K; Okada T; Mizukami H; Hanazono Y; Kume A; Urano F; Ichinose H; Nagatsu T; Nakano I; Ozawa K
Gene Ther; 2002 Mar; 9(6):381-9. PubMed ID: 11960314
[TBL] [Abstract][Full Text] [Related]
37. Fibroblast growth factor-20 protects against dopamine neuron loss in vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Sleeman IJ; Boshoff EL; Duty S
Neuropharmacology; 2012 Dec; 63(7):1268-77. PubMed ID: 22971544
[TBL] [Abstract][Full Text] [Related]
38. GDNF triggers fiber outgrowth of fetal ventral mesencephalic grafts from nigra to striatum in 6-OHDA-lesioned rats.
Wang Y; Tien LT; Lapchak PA; Hoffer BJ
Cell Tissue Res; 1996 Nov; 286(2):225-33. PubMed ID: 8854891
[TBL] [Abstract][Full Text] [Related]
39. Adeno-associated viral delivery of GDNF promotes recovery of dopaminergic phenotype following a unilateral 6-hydroxydopamine lesion.
McGrath J; Lintz E; Hoffer BJ; Gerhardt GA; Quintero EM; Granholm AC
Cell Transplant; 2002; 11(3):215-27. PubMed ID: 12075987
[TBL] [Abstract][Full Text] [Related]
40. Intrastriatal injection of sonic hedgehog reduces behavioral impairment in a rat model of Parkinson's disease.
Tsuboi K; Shults CW
Exp Neurol; 2002 Jan; 173(1):95-104. PubMed ID: 11771942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
